Breast Cancer risk in patients with dopamine agonist-treated hyperprolactinemia.
Breast Cancer; Dopamine Agonist; Hyperprolactinemia; Pituitary; Prolactinoma
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
30 Oct 2024
30 Oct 2024
Historique:
received:
24
08
2024
accepted:
24
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
aheadofprint
Résumé
Given prolactin's (PRL) multifaceted roles in mammary tissue, an association between hyperprolactinemia and breast cancer has been hypothesized. Despite previous studies not identifying this risk, we aimed to investigate whether a connection exists. This retrospective cohort study compared breast cancer incidence in patients with dopamine agonist (DA)-treated hyperprolactinemia versus matched controls in a 1:5 ratio. The primary outcome was a breast cancer diagnosis following hyperprolactinemia diagnosis. The cohort consisted of 1484 female patients with DA-treated hyperprolactinemia matched to 7418 female controls (mean age at diagnosis 32.70 ± 11.12 years; BMI 25.60 ± 5.84 kg/m Overall, patients with DA-treated hyperprolactinemia did not show an increased risk for breast cancer compared to controls. However, the risk was significantly higher among those whose PRL levels were < 5×ULN, had advanced age of diagnosis, or prolonged time to PRL normalization.
Identifiants
pubmed: 39476176
doi: 10.1007/s40618-024-02492-2
pii: 10.1007/s40618-024-02492-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Vroonen L, Daly AF, Beckers A (2019) <ArticleTitle Language="En">Epidemiology and management challenges in prolactinomas. Neuroendocrinology 109(1):20–27. https://doi.org/10.1159/000497746
doi: 10.1159/000497746
pubmed: 30731464
Petersenn S, Fleseriu M, Casanueva FF et al (2023) Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society International Consensus Statement. Nat Rev Endocrinol 19(12):722–740. https://doi.org/10.1038/s41574-023-00886-5
doi: 10.1038/s41574-023-00886-5
pubmed: 37670148
Mindermann T, Wilson CB (1994) Age-related and gender‐related occurrence of pituitary adenomas. Clin Endocrinol 41(3):359–364. https://doi.org/10.1111/j.1365-2265.1994.tb02557.x
doi: 10.1111/j.1365-2265.1994.tb02557.x
Colao A (2009) The prolactinoma. Best Pract Res Clin Endocrinol Metab 23(5):575–596. https://doi.org/10.1016/j.beem.2009.05.003
doi: 10.1016/j.beem.2009.05.003
pubmed: 19945024
Chanson P, Maiter D (2019) The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best Pract Res Clin Endocrinol Metab 33(2):101290. https://doi.org/10.1016/j.beem.2019.101290
doi: 10.1016/j.beem.2019.101290
pubmed: 31326373
Wildemberg LE, Fialho C, Gadelha MR, Prolactinomas (2021) Presse Med 50(4):104080. https://doi.org/10.1016/j.lpm.2021.104080
Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R (2023) Approach to the Patient with Prolactinoma. J Clin Endocrinol Metab 108(9):2400–2423. https://doi.org/10.1210/clinem/dgad174
doi: 10.1210/clinem/dgad174
pubmed: 36974474
pmcid: 10438891
Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692
doi: 10.1210/jc.2010-1692
pubmed: 21296991
Leca BM, Mytilinaiou M, Tsoli M, Epure A, Aylwin SJ, Kaltsas G, Randeva HS, Dimitriadis GK (2021) Identification of an optimal prolactin threshold to determine prolactinoma size using receiver operating characteristic analysis. Sci Rep 11(1):9801. https://doi.org/10.1038/s41598-021-89256-7
doi: 10.1038/s41598-021-89256-7
pubmed: 33963239
pmcid: 8105338
Schuler LA, O’Leary KA (2022) Prolactin: the third hormone in breast cancer. Front Endocrinol 13:910978. https://doi.org/10.3389/fendo.2022.910978
doi: 10.3389/fendo.2022.910978
Clevenger CV, Rui H (2022) Breast cancer and prolactin–new mechanisms and models. Endocrinol 163(10):bqac122. https://doi.org/10.1210/endocr/bqac122
doi: 10.1210/endocr/bqac122
Haga S, Watanabe O, Shimizu T, Iida T, Imamura H, Kajiwara T, Fujibayashi M (1993) Breast cancer in a male patient with prolactinoma. Surg Today 23:251–255. https://doi.org/10.1007/BF00309236
doi: 10.1007/BF00309236
pubmed: 8385514
Strungs I, Gray RA, Rigby HB, Strutton G (1997) Two case reports of breast carcinoma associated with prolactinoma. Pathol 29(3):320–323. https://doi.org/10.1080/00313029700169205
doi: 10.1080/00313029700169205
Volm MD, Talamonti MS, Thangavelu M, Gradishar WJ (1997) Pituitary adenoma and bilateral male breast cancer: an unusual association. J Surg Oncol 64(1):74–78. https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-9098(199701)64:1%3C74::AID-JSO14%3E3.0.CO;2-W
doi: 10.1002/(SICI)1096-9098(199701)64:1<74::AID-JSO14>3.0.CO;2-W
pubmed: 9040805
Forloni F, Giovilli M, Pecis C, Bortolani E, Preziosi A, Barzaghi ME, Corti D, Beck-Peccoz P (2001) Pituitary prolactin-secreting macroadenoma combined with bilateral breast cancer in a 45-year-old male. J Endocrinol Invest 24:454–459. https://doi.org/10.1007/BF03351047
doi: 10.1007/BF03351047
pubmed: 11434671
Sato T, Muto I, Hasegawa M, Aono T, Okada T, Tamura T, Sakai T (2007) A rare case of invasive ductal carcinoma with hyperprolactinemia. Breast Cancer 14(3):302–306. https://doi.org/10.2325/jbcs.14.302
doi: 10.2325/jbcs.14.302
pubmed: 17690509
Mallawaarachchi CM, Ivanova S, Shorthouse A, Shousha S, Sinnett D (2011) A rare case of male breast ductal carcinoma in-situ associated with prolactinoma. BMJ Case Rep 2011:bcr0120091421. https://doi.org/10.1136/bcr.01.2009.1421
doi: 10.1136/bcr.01.2009.1421
pubmed: 22679041
Zheng Y, Mo W, Yu Y, Zou D, He X, Xia X, Hu J (2017) Breast carcinoma associated with prolactinoma: A case report. Cancer Biol Ther 18(3):132–136. https://doi.org/10.1080/15384047.2017.1294284
doi: 10.1080/15384047.2017.1294284
pubmed: 28278079
Hao S, Huang M, Tian W, Chen Y, Zhao J, Luo D (2020) Whole exome sequencing in the male breast cancer with prolactinoma: a case report and literature review. J Breast Cancer 23(6):656–664. https://doi.org/10.4048/jbc.2020.23.e63
doi: 10.4048/jbc.2020.23.e63
pubmed: 33408891
Dekkers OM, Romijn JA, De Boer A, Vandenbroucke JP (2010) The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary 13:195–198. https://doi.org/10.1007/s11102-009-0214-y
doi: 10.1007/s11102-009-0214-y
pubmed: 20012697
Berinder K, Akre O, Granath F, Hulting AL (2011) Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 165(2):209–215. https://doi.org/10.1530/EJE-11-0076
doi: 10.1530/EJE-11-0076
pubmed: 21602317
Dekkers OM, Ehrenstein V, Bengtsen M, Farkas DK, Pereira AM, Sørensen HT, Jørgensen JO (2015) Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur J Endocrinol 173(2):269–273. https://doi.org/10.1530/EJE-15-0282
doi: 10.1530/EJE-15-0282
pubmed: 26012587
Tworoger SS, Eliassen AH, Zhang X, Qian J, Sluss PM, Rosner BA, Hankinson SE (2013) A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 73(15):4810–4819. https://doi.org/10.1158/0008-5472.CAN-13-0665
doi: 10.1158/0008-5472.CAN-13-0665
pubmed: 23783576
pmcid: 3738582
Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE (2004) Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res 64(18):6814–6819. https://doi.org/10.1158/0008-5472.CAN-04-1870
doi: 10.1158/0008-5472.CAN-04-1870
pubmed: 15375001
Aranha AF, Dos Anjos LG, Turri JA, Simoes RS, Maciel GA, Baracat EC, Soares-Junior JM, Carvalho KC (2022) Impact of the prolactin levels in breast cancer: a systematic review and meta-analysis. Gynecol Endocrinol 38(5):385–390. https://doi.org/10.1080/09513590.2022.2047173
doi: 10.1080/09513590.2022.2047173
pubmed: 35266411
Popovic V, Damjanovic S, Micic D, Nesovic M, Djurovic M, Petakov M, Obradovic S, Zoric S, Simic M, Penezic Z, Marinkovic J (1998) Increased incidence of neoplasia in patients with pituitary adenomas. Clin Endocrinol 49(4):441–445. https://doi.org/10.1046/j.1365-2265.1998.00536.x
doi: 10.1046/j.1365-2265.1998.00536.x
Smolarz B, Nowak AZ, Romanowicz H (2022) Breast cancer—epidemiology, classification, pathogenesis and treatment (review of literature). Cancers 14(10):2569. https://doi.org/10.3390/cancers14102569
doi: 10.3390/cancers14102569
pubmed: 35626173
pmcid: 9139759
Sehl ME, Henry JE, Storniolo AM, Horvath S, Ganz PA (2021) The effects of lifetime estrogen exposure on breast epigenetic age. Cancer Epidemiol Biomarkers Prev 30(6):1241–1249. https://doi.org/10.1158/1055-9965.EPI-20-1297
doi: 10.1158/1055-9965.EPI-20-1297
pubmed: 33771849
pmcid: 8172523
Santen RJ, Yue W, Wang JP (2015) Estrogen metabolites and breast cancer. Steroids 99:61– 6. https://doi.org/10.1016/j.steroids.2014.08.003
Mense SM, Remotti F, Bhan A, Singh B, El-Tamer M, Hei TK, Bhat H (2008) Estrogen-induced breast cancer: alterations in breast morphology and oxidative stress as a function of estrogen exposure. Toxicol Appl Pharmacol 232(1):78–85. https://doi.org/10.1016/j.taap.2008.06.007
doi: 10.1016/j.taap.2008.06.007
pubmed: 18640140
pmcid: 2593408
Mancini T, Casanueva FF, Giustina A (2008) Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 37(1):67–99. https://doi.org/10.1016/j.ecl.2007.10.013
doi: 10.1016/j.ecl.2007.10.013
pubmed: 18226731
Haring R, Friedrich N, Völzke H, Vasan RS, Felix SB, Dörr M, Meyer zu Schwabedissen HE, Nauck M, Wallaschofski H (2014) Positive association of serum prolactin concentrations with all-cause and cardiovascular mortality. Eur Heart J 35(18):1215–1221. https://doi.org/10.1093/eurheartj/ehs233
doi: 10.1093/eurheartj/ehs233
pubmed: 22843444
Macotela Y, Triebel J, Clapp C (2020) Time for a new perspective on prolactin in metabolism. Trends Endocrinol Metab 31(4):276–286. https://doi.org/10.1016/j.tem.2020.01.004
doi: 10.1016/j.tem.2020.01.004
pubmed: 32044206